TTRX

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

10-Q - Turn Therapeutics Inc. (0002023016) (Filer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead First Peer-Reviewed Publication Shows GX-03 Significantly Reduced Skin Inflammation in Preclinical Study Company Plans to Expand GX-03 Pipeline into Hidradenitis Suppurativa, with First Patient Dosing Targeted for Q2 2027 Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027 Turn Therapeutics Inc. (NASDAQ:TTRX), a

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date. "We're honored that Nasdaq invited us back to share our story," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. "Over the past year we've made meaningful progress, but

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) Comprehensive interim review identifies optimal patient population, endpoint strategy, disease stratification, and statistical methodology for final Stage 2 design of the Company's ongoing adaptive Phase 2 trial in atopic dermatitis Final Stage 2 design will employ the FDA-recognized Hochberg multiple testing procedure, allowing statistical significance to be established across multiple efficacy endpoints rather than a si

Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program. Following the preliminary interim assessment announced in June, the Company conducted a detailed multi-week review of the Stage 1 dataset within the trial's ad

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

4 - Turn Therapeutics Inc. (0002023016) (Issuer)

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9% achieved a 90% reduction in 8 weeks (EASI-90) Interim analysis informed refinement of enrollment criteria, endpoint hierarchy, and overall trial optimization strategy No treatment-related serious adverse events observed in either treatment group; no treatment-related tolerability issues or discontinuations reported during the interim analysis period Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for infla

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Study demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression First in a planned series of peer-reviewed publications exploring the scientific rationale and non-systemic mechanism underlying GX-03, currently in Phase 2 evaluation for moderate-to-severe atopic dermatitis Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36–assoc

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City as follows: Date: June 4, 2026 Time: 9:55 AM – 10:25 AM EDT A live webcast of the presentation may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/presentations. A replay of the webcast will be available on the Turn Therapeutics website for approximately six months following the presentation. About Turn Therapeutics Turn Therapeutic

8-K - Turn Therapeutics Inc. (0002023016) (Filer)

Dr. Hahn Brings Unparalleled Clinical and Regulatory Expertise to Support Advancement of GX-03 for Moderate-to-Severe Atopic Dermatitis and Pipeline Indications 
 Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration (FDA), to oversee the clinical and regulatory strategy for GX-03, the Company's investigational topical therapy currently in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis (eczema). "Patients with inflammatory skin diseases still lack adequate

C-TR - Turn Therapeutics Inc. (0002023016) (Filer)